Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Research Report 2024(Status and Outlook)
Report Overview
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis (NASH) Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis (NASH) Drugs market in any manner.
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Market Segmentation (by Type)
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market Segmentation (by Application)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis (NASH) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis (NASH) Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis (NASH) Drugs market in any manner.
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Market Segmentation (by Type)
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market Segmentation (by Application)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Alcoholic Steatohepatitis (NASH) Drugs Market
- Overview of the regional outlook of the Non-Alcoholic Steatohepatitis (NASH) Drugs Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis (NASH) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis (NASH) Drugs
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AstraZeneca
9.1.1 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.1.2 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Conatus Pharmaceuticals
9.2.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.2.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.2.4 Conatus Pharmaceuticals Business Overview
9.2.5 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.2.6 Conatus Pharmaceuticals Recent Developments
9.3 Enzo Biochem
9.3.1 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.3.2 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.3.5 Enzo Biochem Business Overview
9.3.6 Enzo Biochem Recent Developments
9.4 Galmed Pharmaceuticals
9.4.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.4.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.4.4 Galmed Pharmaceuticals Business Overview
9.4.5 Galmed Pharmaceuticals Recent Developments
9.5 Genfit
9.5.1 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.5.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.5.4 Genfit Business Overview
9.5.5 Genfit Recent Developments
9.6 Gilead
9.6.1 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.6.2 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.6.4 Gilead Business Overview
9.6.5 Gilead Recent Developments
9.7 Horizon Pharma
9.7.1 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.7.2 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.7.4 Horizon Pharma Business Overview
9.7.5 Horizon Pharma Recent Developments
9.8 Immuron
9.8.1 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.8.2 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.8.4 Immuron Business Overview
9.8.5 Immuron Recent Developments
9.9 Intercept Pharmaceuticals
9.9.1 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.9.2 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.9.4 Intercept Pharmaceuticals Business Overview
9.9.5 Intercept Pharmaceuticals Recent Developments
9.10 Novo Nordisk
9.10.1 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.10.2 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.10.4 Novo Nordisk Business Overview
9.10.5 Novo Nordisk Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis (NASH) Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis (NASH) Drugs
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Manufacturers (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2019-2024)
6.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price by Type (2019-2024)
7 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Sales by Application (2019-2024)
7.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
8 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AstraZeneca
9.1.1 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.1.2 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Conatus Pharmaceuticals
9.2.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.2.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.2.4 Conatus Pharmaceuticals Business Overview
9.2.5 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.2.6 Conatus Pharmaceuticals Recent Developments
9.3 Enzo Biochem
9.3.1 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.3.2 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
9.3.5 Enzo Biochem Business Overview
9.3.6 Enzo Biochem Recent Developments
9.4 Galmed Pharmaceuticals
9.4.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.4.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.4.4 Galmed Pharmaceuticals Business Overview
9.4.5 Galmed Pharmaceuticals Recent Developments
9.5 Genfit
9.5.1 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.5.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.5.4 Genfit Business Overview
9.5.5 Genfit Recent Developments
9.6 Gilead
9.6.1 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.6.2 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.6.4 Gilead Business Overview
9.6.5 Gilead Recent Developments
9.7 Horizon Pharma
9.7.1 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.7.2 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.7.4 Horizon Pharma Business Overview
9.7.5 Horizon Pharma Recent Developments
9.8 Immuron
9.8.1 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.8.2 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.8.4 Immuron Business Overview
9.8.5 Immuron Recent Developments
9.9 Intercept Pharmaceuticals
9.9.1 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.9.2 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.9.4 Intercept Pharmaceuticals Business Overview
9.9.5 Intercept Pharmaceuticals Recent Developments
9.10 Novo Nordisk
9.10.1 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
9.10.2 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
9.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Market Performance
9.10.4 Novo Nordisk Business Overview
9.10.5 Novo Nordisk Recent Developments
10 NON-ALCOHOLIC STEATOHEPATITIS (NASH) DRUGS MARKET FORECAST BY REGION
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region
10.2.4 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis (NASH) Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2025-2030)
11.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2025-2030)
11.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) Forecast by Application
11.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis (NASH) Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 43. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 44. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 45. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 50. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 51. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Conatus Pharmaceuticals Business Overview
Table 53. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 54. Conatus Pharmaceuticals Recent Developments
Table 55. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 56. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 57. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 59. Enzo Biochem Business Overview
Table 60. Enzo Biochem Recent Developments
Table 61. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 62. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 63. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Galmed Pharmaceuticals Business Overview
Table 65. Galmed Pharmaceuticals Recent Developments
Table 66. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 67. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 68. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Genfit Business Overview
Table 70. Genfit Recent Developments
Table 71. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 72. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 73. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Gilead Business Overview
Table 75. Gilead Recent Developments
Table 76. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 77. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 78. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Horizon Pharma Business Overview
Table 80. Horizon Pharma Recent Developments
Table 81. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 82. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 83. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Immuron Business Overview
Table 85. Immuron Recent Developments
Table 86. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 87. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 88. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Intercept Pharmaceuticals Business Overview
Table 90. Intercept Pharmaceuticals Recent Developments
Table 91. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 92. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 93. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Novo Nordisk Business Overview
Table 95. Novo Nordisk Recent Developments
Table 96. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis (NASH) Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2019-2024)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2019-2024)
Table 35. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Region (2019-2024) & (K Units)
Table 43. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 44. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 45. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 50. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 51. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Conatus Pharmaceuticals Business Overview
Table 53. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 54. Conatus Pharmaceuticals Recent Developments
Table 55. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 56. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 57. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs SWOT Analysis
Table 59. Enzo Biochem Business Overview
Table 60. Enzo Biochem Recent Developments
Table 61. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 62. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 63. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Galmed Pharmaceuticals Business Overview
Table 65. Galmed Pharmaceuticals Recent Developments
Table 66. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 67. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 68. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Genfit Business Overview
Table 70. Genfit Recent Developments
Table 71. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 72. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 73. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Gilead Business Overview
Table 75. Gilead Recent Developments
Table 76. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 77. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 78. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Horizon Pharma Business Overview
Table 80. Horizon Pharma Recent Developments
Table 81. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 82. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 83. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Immuron Business Overview
Table 85. Immuron Recent Developments
Table 86. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 87. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 88. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Intercept Pharmaceuticals Business Overview
Table 90. Intercept Pharmaceuticals Recent Developments
Table 91. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Basic Information
Table 92. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Overview
Table 93. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Novo Nordisk Business Overview
Table 95. Novo Nordisk Recent Developments
Table 96. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis (NASH) Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis (NASH) Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD), 2019-2030
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2019-2024)
Figure 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Application (2025-2030)
